Chapter 52 Notes: Colon and Rectum (Comprehensive Exam Preparation)
Appendix and Ileocecal Region
Vermiform appendix originates from the cecum about 3 cm below the ileocecal valve; blind-ending tube 8–10 cm long.
Most common positions: retrocecal (65%), pelvic (31%), subcecal (2.3%), preileal (1%), retroileal (0.4%).
Inflammation and adhesions make locating the appendix difficult; reliable base access by tracing anterior taeniae converging at the base.
The bloodless fold of Treves extends from the antimesenteric border of the terminal ileum to the base of the appendix or anterior surface of the mesoappendix or both; contains no sizable vessels and aids ileocecal region recognition.
Developmental anatomy and healing folds (notable figures/plates): Correlated coronal sections and midgut development diagrams reconstructed in Fig. 52.2–52.3 show foregut, midgut, hindgut divisions and midgut physiologic herniation/return.
Large Bowel Anatomy and Surveillance Landmarks
Large bowel components: ascending, transverse, descending, sigmoid colon, and rectum; rectum ends at anal canal.
Appendix position references and cecal/ileocecal region guidance are crucial for surgical planning.
Appendix and mesoappendix relation to cecum and surrounding structures is key for safe resections (Fig. 52.5).
The large bowel relationships and peritoneal coverings are summarized in Gray’s anatomy references (Fig. 52.4).
Ascending and Transverse Colon; Omentum and Splenic Flexure
Ascending colon: begins at ileocecal junction; ~
Length: ~ up to hepatic flexure; intraperitoneal anterior and lateral surfaces; posterior surface retroperitoneally fixed via fascia of Treitz.
Release along the white line of Toldt aids mobilization; beware proximity to second part of the duodenum.
Transverse colon: ~, suspended between hepatic and splenic flexures; completely visceral peritoneum-covered and connected to posterior abdominal wall via transverse mesocolon.
Transverse colon position is variable; important for exteriorization of colon in stoma planning (target incision).
Greater omentum attaches to superior aspect of transverse colon; comprises superior gastrocolic ligament and an inferior apron-like portion; omentum can be mobilized to create a pedicle.
Splenic flexure: adjacent and inferior to spleen; held by four main ligaments (phrenicocolic, splenocolic, renocolic, pancreaticocolic); mobilization possible without major vessel division; risk of splenic capsule avulsion with excessive downward traction.
The transverse colon can be mobilized to expose the greater omentum and the lesser sac via division of the gastrocolic ligaments when needed (for mobilization of splenic flexure).
Figure references: Fig. 52.6 (splenic flexure ligaments); Fig. 52.7 (intersigmoid recess); Fig. 52.4 (large bowel relations).
Sigmoid and Descending Colon; Vascular and Mesenteric Planes
Descending colon: begins at splenic flexure; ~ length; loses mesentery at splenic flexure; left colon is smaller in diameter than ascending.
Sigmoid colon: begins at or below iliac crest; becomes intraperitoneal again with a mesentery; length varies from (average ~); highly mobile; attached to posterior abdominal wall via sigmoid mesocolon in an inverted V pattern creating the intersigmoid fossa (Fig. 52.7).
Sigmoid mesocolon: critical anatomic landmark; left ureter proximity must be avoided during mobilization.
The marginal artery of Drummond runs along the mesenteric margin from cecocolic to rectosigmoid junction; vasa recta branch off at short intervals to supply bowel.
Meandering mesenteric artery (arc of Riolan) is an uncommon collateral that connects SMA/middle colic to IMA/left colic; presence suggests proximal mesenteric artery occlusion risk.
Venous drainage tracks arterial supply; IMV drains to portal system via left colic/IMV junction; IMV can be divided to gain colon length for low pelvic anastomoses.
Lymphatic drainage generally follows arterial supply; paracolic nodes around marginal arteries; dual drainage possible at distal transverse/splenic flexure to both SMN and IMN.
Innervation mirrors arterial supply (see below).
Arterial Supply, Venous Drainage, and Lymphatics of the Colon
Arterial supply follows embryologic layout:
Foregut: celiac axis
Midgut: superior mesenteric artery (SMA)
Hindgut: inferior mesenteric artery (IMA)
Major SMA branches to colon: middle colic (transverse colon), ileocolic (terminal ileum, cecum, appendicular), right colic (variable; absent in up to 20% of cases).
IMA branches: left colic (proximal to splenic flexure), sigmoid arteries, superior rectal artery.
The marginal artery of Drummond forms a collateral around the colon; arc of Riolan connects SMA/MC and IMA/LC in certain pathologies.
Venous drainage parallels arterial supply; IMV drains into portal system via left colic/IMV confluence; IMV can be divided to gain colon length and for low pelvic anastomoses.
Lymphatics drain along arterial supplies; nodes commonly parallel to marginal arteries; dual drainage possible between upper/mest transcendence of transverse colon and splenic flexure.
Rectal Anatomy and Pelvis - Peritoneal Reflections and Fascia
Rectum length: about ; begins at rectosigmoid junction; proximal border usually defined at the level of the dentate line (proximal border of anal sphincter) ~ above dentate line.
Rectal divisions by peritoneal relationships:
Upper rectum: anterior and lateral peritoneal coverage; lower limit ~ above dentate line.
Middle rectum: peritoneum anteriorly only; extends ~ above dentate line.
Lower rectum: totally extraperitoneal; extends ~ above dentate line.
Valves of Houston: three lateral rectal folds; proximal and distal folds to the right, middle to the left; these are lost after full mobilization of rectum, providing ~ additional length for pelvic anastomosis.
Rectum lacks taeniae coli, epiploic appendages, and haustra.
Anterior peritoneal reflection between rectum and bladder/uterus; rectovesical pouch in men; rectouterine pouch (Douglas) in women; pouch is 7–9 cm from anal verge in men and 5–7.5 cm in women (Fig. 52.10).
Waldeyer fascia (rectosacral fascia): thick endopelvic fascia connecting presacral fascia to fascia propria; dividing it provides access to deep retrorectal pelvis during proctectomy.
Denonvilliers fascia: anterior to rectum; extension of inferior peritoneal reflection; separates rectum from anterior structures and is the anterior border of total mesorectal excision (TME).
Blood supply to rectum: superior, middle, and inferior rectal arteries with robust anastomoses around the rectal wall; venous drainage mirrors arterial supply; superior rectal vein drains to IMV/portal; middle and inferior rectal veins drain to internal iliac system; anastomosis supports perfusion after anterior resections.
Nerve supply: sympathetic via superior hypogastric plexus, hypogastric nerves; pelvic splanchnic nerves (S2–S4) provide parasympathetic innervation; autonomic nerves are at risk in pelvic dissection; injury can cause retrograde ejaculation, erectile dysfunction, bladder dysfunction.
Mesh and Waldeyer fascia dissection planes are critical to minimize bleeding and preserve pelvic autonomic nerves.
Pelvic Floor Anatomy and Continence
Pelvic floor (pelvic diaphragm) supports pelvic organs and aids defecation.
Levator ani muscles: pubococcygeus, iliococcygeus, puborectalis.
Pubococcygeus forms the levator hiatus; puborectalis forms a U-shaped sling behind the rectum; maintains fecal continence by maintaining anorectal angle; relaxation straightens the angle to allow defecation.
Puborectalis dysfunction is a major cause of defecation disorders.
Physiology of the Colon
Absorption and secretion: major role is water absorption and electrolyte exchange; colon can absorb up to 5 L/day; typically 1–2 L reach the stool; ~90% of luminal fluid is absorbed; stool ~150 mL/day;
Sodium and chloride absorption: Na+/H+, Na+/K+, Cl−/HCO3− exchangers; water follows osmotic gradient.
Secretion: H+ and bicarbonate secretion; bicarbonate and chloride exchange linked to metabolism; carbonic anhydrase provides H+/HCO3−; systemic pH changes modulate carbonic anhydrase activity.
Urea recycling: colonic bacteria produce urease; ammonia absorption depends on bacterial concentration and intraluminal pH; antibiotics and lactulose reduce ammonia absorption; ammonia transported to liver; liver failure worsens hepatic encephalopathy via ammonia accumulation.
Bile acid reabsorption: colon absorbs bile acids from ileal bile acids that escape reabsorption; deconjugation by colonic bacteria can cause secretory diarreha; cholestyramine can bind bile acids to treat this.
Colonic mucosal secretion is influenced by aldosterone and other hormones; but aldosterone promotes potassium secretion and can be blocked by spironolactone.
Colonic secretion and absorption link to systemic acid-base balance via Na+/H+ and Cl−/HCO3− exchangers and carbonic anhydrase.
Colonic fermentation products: SCFAs (butyrate, acetate, propionate); butyrate is primary energy source for colonocytes; butyrate supports mucosal health and may protect against neoplasia; acetate is abundant and used for cholesterol synthesis; propionate participates in hepatic glycolysis; SCFA absorption >90%; antibiotics disrupt SCFA production; mucosal atrophy can occur after diversion.
Butyrate promotes colonocyte health; some SCFAs may influence systemic metabolism and immune function.
Gas end products: CO2, methane, hydrogen; fermentation also yields potentially toxic metabolites from protein fermentation (phenols, indoles, amines).
Colonic mucosal function supports colonic homeostasis and cancer prevention via SCFA-mediated effects.
Probiotics and Prebiotics
Probiotics: live cultures (Lactobacillus, Bifidobacterium); may improve immune function, anti-inflammatory effects, reduce Enterobacteriaceae colonization; reduce C. difficile infection risk; evidence for broader disease indications is evolving.
Prebiotics: nondigestible oligosaccharides (inulin) that stimulate beneficial bacteria; clinical guidance evolving; more research needed.
Colonic Motility and Defecation
Autonomic and enteric nervous systems regulate motility: parasympathetic via vagus and sacral nerves; sympathetic inhibition.
Intrinsic myenteric (Auerbach) and submucosal (Meissner) plexuses regulate motility, blood flow, absorption, secretion.
Interstitial cells of Cajal act as pacemakers of smooth muscle activity.
Primary motility patterns: low-amplitude propagated contractions (LAPCs) for mixing; high-amplitude propagated contractions (HAPCs) for distal movement 1–3 times/day.
Circadian rhythms and meals influence motility.
Defecation physiology: adequate transit time; adequate stool consistency; continence; pelvic floor coordination; relaxation of puborectalis is essential for defecation; tensing or spastic pelvic floor impairs stool passage.
Preoperative Evaluation and Enhanced Recovery Protocols (ERPs)
Nutritional risk: preop albumin is a reliable predictor of postoperative complications; albumin < indicates higher risk.
Risk indices: POSSUM, CR-POSSUM, ACS-NSQIP calculators; CRP may aid risk stratification in diverticulitis or IBD.
Immunonutrition: arginine-rich supplementation may boost immune function and reduce SSI; evidence evolving.
High-risk groups: chronic partial bowel obstruction, cancer with significant weight loss (>10 ext{%}), malnourished patients.
Preoperative bowel preparation: historically cyclical; modern guidelines favor mechanical prep plus oral antibiotics to reduce postoperative infections, especially with left-sided/rectal resections; mechanical prep alone not beneficial by itself; some debates exist for IBD and partial obstruction patients.
Preoperative stoma site marking: essential in sitting position to account for abdominal wall folds and incision planning; infraumbilical fat mound often ideal; mis-marking can cause appliance fit issues postoperatively.
Stoma configurations: end stoma (fecal), loop stoma (diversion with proximal and distal limbs), end-loop stoma (combination of end and loop features).
Stoma considerations: in overweight/obese patients, mobilization and vascular control may be needed to achieve tension-free reach; stoma aperture should typically allow two fingers space to avoid skin problems but not be so large as to risk hernia.
Complications and planning: ensure viability of stoma during closure; if doubt, construct stoma before fascial closure.
Enhanced Recovery Protocols (ERPs): multi-component bundles across preop, intraop, and postop phases; aim to reduce SSI, LOS, and costs while not increasing readmissions; essential components include preop chlorhexidine showers, bowel prep with antibiotics, antibiotics timing, wound protectors, normothermia, euglycemia; multimodal analgesia, minimizing opioids; TAP blocks; avoid routine drains/nasogastric tubes when feasible; goal-directed fluid therapy; MIS approaches when possible.
Diverticular Disease: Epidemiology and Pathophysiology
Diverticula: false diverticula predominant in Western populations; true diverticula are rare and congenital; false diverticula involve mucosa and muscularis mucosa.
Pathophysiology: muscular hypertrophy, narrowed lumen, disordered motility causing high intraluminal pressures; diverticula form on mesenteric side where vasa recta traverse muscle (sigmoid and descending colon most commonly affected; rectum usually spared due to thick wall).
Epidemiology: diverticulosis increases with age; ~40% of people aged 50–60, >60% over age 80 have diverticula.
Diverticulitis pathophysiology: inflammation and microperforation due to diverticular obstruction leading to bacterial overgrowth and increased local pressure.
Diet and lifestyle: high fiber reduces risk; nuts/seeds/popcorn do not increase risk; central obesity and smoking increase risk; physical activity reduces risk; protective lifestyle combinations may prevent up to 50% of incident diverticulitis.
Diverticulitis: Clinical Presentation and Evaluation
Diverticulitis presents with LLQ abdominal pain; fever, changes in bowel habits, anorexia; urinary urgency if bladder involvement; exam shows localized tenderness and possible phlegmon; rectal bleeding is uncommon.
Diagnosis: CT is most useful; signs include diverticula, colonic wall thickening, pericolic fat stranding, abscess; Hinchey classification (updated):
Grade 0: mild clinical diverticulitis
Grade Ia: confined pericolic inflammation (phlegmon)
Grade Ib: confined pericolic abscess within sigmoid mesocolon
Grade II: distant intraabdominal or pelvic abscess
Grade III: generalized purulent peritonitis
Grade IV: fecal peritonitis
Endoscopy in acute diverticulitis is approached with caution due to perforation risk.
Complications of Diverticulitis and Their Management
Abscesses: small abscesses can be treated with antibiotics; larger abscesses require drainage; elective surgery after recovery.
Fistulas: most common is colovesical fistula presenting with recurrent UTIs, pneumaturia, fecaluria; CT and cystoscopy help; resection of involved colon and fistula tract with primary anastomosis when possible; bladder drainage with Foley catheter for small fistula to allow healing.
Colovaginal fistulas occur in women post-hysterectomy with vaginal discharge and air in vagina.
Obstruction: diverticular strictures; partial obstruction treated with NG decompression, fluids, antibiotics; colonoscopy or contrast studies to rule out cancer; complete obstruction treated with surgery.
Perforation with generalized peritonitis or sepsis requires urgent surgery; Hartmann procedure historically favored; alternative approaches include primary anastomosis with diverting ileostomy or laparoscopic lavage in selected cases.
Uncomplicated diverticulitis may be managed medically; recurrence risk exists but varies; elective resection guided by individual factors; audience notes the shift away from automatic colectomy after recurrent episodes.
Inflammatory Bowel Disease (IBD): UC and Crohn’s Disease
Epidemiology: UC and Crohn’s disease are common in Western populations; rising incidence in developing regions; familial predisposition and >230 susceptibility loci identified for IBD.
Pathophysiology and disease progression: genetic predisposition with environmental triggers; in Crohn’s disease progression may move from inflammatory to fibrostenotic to fistulizing disease; the idea of top-down therapy to prevent fibrosis.
Classification and presentation:
Ulcerative Colitis (UC): continuous inflammation starting at the dentate line and moving proximally; involvement limited to colon; endoscopic Mayo scoring system (Grades 1–4) for mucosal inflammation; crypt abscesses; superficial mucosal involvement.
Crohn’s disease: patchy involvement with skip areas; transmural inflammation; deeper ulcers (“bear claw” ulcers); most common site ileocolic; can involve small bowel elsewhere; noncaseating granulomas in about one-third of Crohn’s.
Extraintestinal manifestations: joint involvement (sacroiliitis, ankylosing spondylitis), eyes (uveitis, episcleritis), skin (erythema nodosum, pyoderma gangrenosum); more common in Crohn’s; ocular and dermatologic issues require multidisciplinary care.
Endoscopy and histology:
UC: continuous mucosal inflammation limited to mucosa; crypt abscesses; goblet cell depletion; no transmural lymphoid aggregates.
Crohn’s: transmural inflammation; granulomas; skip lesions; terminal ileum commonly involved; sometimes perianal disease; indeterminate colitis possible when diagnosis is unclear.
Diagnosis and scoring indices: CDAI for Crohn’s; Harvey-Bradshaw Index (simplified CDAI); Mayo score for UC.
Medical therapy evolution: from bottom-up (start with milder therapies) to top-down (early aggressive therapy with biologics) to reduce disease activity and surgical need; biologics include anti-TNF agents (infliximab, adalimumab, certolizumab), anti-integrin (vedolizumab), anti-IL12/23 (ustekinumab), JAK inhibitors (tofacitinib for UC).
Conventional therapies: aminosalicylates (sulfasalazine; mesalamine formulations like Pentasa, Asacol, MMX technology, enemas, suppositories); corticosteroids; immunomodulators (azathioprine, 6-mercaptopurine; TPMT testing recommended to mitigate myelosuppression risk); methotrexate for Crohn’s; probiotics/prebiotics remain exploratory.
Biologics: potential adverse effects include infection reactivation (TB, histoplasmosis, hepatitis); risk of lymphoma; TB/HDV screening required; careful pre-treatment screening.
Surgery indications:
Ulcerative Colitis: failure of medical therapy; fulminant colitis with toxic megacolon; dysplasia or cancer in long-standing disease; significant chronic extraintestinal disease; severe bleeding; growth failure in children; prophylactic colectomy for dysplasia or high cancer risk; IPAA is common, with options including stapled or hand-sewn anastomosis; ileal pouch–anal anastomosis (IPAA) often with temporary diverting ileostomy; alternatives include IRA, total proctocolectomy with end ileostomy.
Crohn’s disease: surgery reserved for complications (obstruction from fibrostenosis, perforation with abscess or fistula, abscesses, cancer or dysplasia); segmental colectomy in select cases; ileocecal resection common; risk of postoperative recurrence; after surgery, recurrence is possible; early postoperative immunomodulator therapy can reduce recurrence; perianal Crohn’s disease addressed with surgical drainage and fistula repair when feasible.
Postoperative recurrence: higher in Crohn’s than UC; smoking and younger age increase risk; early intensive medical therapy postoperatively may reduce recurrence; endoscopic monitoring recommended to identify recurrent disease early.
Colorectal Neoplasia and Polyps
CRC genetics and pathways:
Chromosomal Instability (CIN): ~60% of CRC; early APC mutations, KRAS activation, TP53 inactivation; aneuploidy and LOH are hallmark features.
CpG Island Methylator Phenotype (CIMP): ~35% of CRC; hypermethylation leading to gene silencing; often BRAF-mutant in sporadic Serrated pathway; right colon predominance.
Microsatellite Instability (MSI)/Mutator pathway: ~5% through Lynch syndrome; sporadic MSI-H via MLH1 methylation; BRAF mutation helps differentiate sporadic MSI-H from Lynch syndrome.
Four consensus molecular subtypes (CMS1–CMS4): CMS1 is MSI-H with immune activation; CMS2 is epithelial with WNT/MYC activation; CMS3 is metabolic/epithelial; CMS4 is mesenchymal with TGF-β activation and angiogenesis. These subtypes guide prognosis and therapy.
Polyp categories:
Non-neoplastic: hyperplastic polyps (no malignant potential); inflammatory polyps/pseudopolyps (regenerative after ulceration; no intrinsic malignant potential but may mimic neoplasia).
Neoplastic polyps: adenomas (tubular, villous, tubulovillous with dysplasia); risk of cancer increases with size, sessile morphology, villous histology, high-grade dysplasia.
Serrated polyps: hyperplastic (low risk), sessile serrated polyps, traditional serrated adenomas; serrated pathway to CRC; important in colorectal cancer surveillance.
Malignant polyps: polyp cancers invading muscularis mucosae or deeper; Haggitt levels (pedunculated polyps) and Kikuchi grading (polypoid invasion depth) used to assess invasion depth and risk; management decisions about endoscopic vs surgical resection depend on invasion depth and margins.
Surveillance after polypectomy: follow-up intervals guided by polyp type, size, and number; small hyperplastic polyps in rectosigmoid often require longer intervals; adenomas with high-risk features require earlier surveillance; table-driven guidelines (Table 52.6).
Hereditary Colorectal Cancer Syndromes
Familial Adenomatous Polyposis (FAP): autosomal dominant; APC gene mutation; thousands of adenomas; high CRC risk if untreated (near 100%); Spigelman staging used for duodenal polyposis; extraintestinal manifestations include desmoid tumors, osteomas, CHRPE, and others; management options include IPAA after proctocolectomy, ileorectal anastomosis (IRA), or proctocolectomy with permanent ileostomy; risk of desmoid tumors, small-bowel cancer; genetic counseling recommended.
Attenuated FAP (AFAP): fewer adenomas; delayed onset; management depends on polyp burden and cancer risk.
MUTYH-Associated Polyposis (MAP): autosomal recessive (biallelic MUTYH mutations); variable polyposis; cancer risk elevated with biallelic mutations; colonoscopy surveillance every 1–2 years; colectomy with IRA or IPAA considered if CRC develops or endoscopic management fails.
Juvenile Polyposis Syndrome (JPS): SMAD4 or BMPR1A mutations; multiple juvenile polyps; cancer risk elevated; surveillance starting age 12–15 with colonoscopy; surgery considered for high polyp burden or dysplasia.
Peutz-Jeghers Syndrome (PJS): STK11/LKB1 mutation; hamartomatous polyps throughout GI tract; mucocutaneous pigmentation; high lifetime cancer risk across multiple organs; surveillance includes GI, pancreatic, breast, gynecologic, and other organ screenings; polypectomy to remove obstructive polyps; small-bowel polyps may complicate with intussusception; surveillance intervals are age-based and organ-specific.
Lynch Syndrome (HNPCC): autosomal dominant; defects in MMR genes (MLH1, MSH2, MSH6, PMS2, EpCAM); MSI-high tumors; higher risk of CRC and other cancers (endometrial, ovarian, gastric, urothelial, brain, pancreas); earlier onset; annual endometrial/ovarian cancer screening and consideration of prophylactic surgeries; colonoscopy every 1–2 years starting at 20–25 years or 2–5 years before the youngest CRC in the family; testing with Amsterdam/Bethesda criteria; management includes consideration of total colectomy/IRA or IPAA depending on cancer risk, colonoscopy surveillance, and management of associated cancers.
Other polyposis syndromes: Gardner syndrome (FAP with desmoid tumors, osteomas, skin lesions); Turcot syndrome (FAP with CNS tumors); CHRPE is a marker for FAP.
Colorectal Cancer (CRC) Staging and Surgical Principles
Staging: TNM system (AJCC); cTNM (clinical), pTNM (pathologic), ypTNM (post-neoadjuvant therapy); goal is to determine prognosis and plan adjuvant therapy.
Prognostic factors beyond TNM: serum CEA, tumor deposits, lymphovascular invasion, perineural invasion; histologic grade (G1–G3); histologic subtypes (mucinous/signet-ring); circumferential resection margin in rectal cancer; completeness of mesorectal excision; molecular markers (MSI, KRAS, BRAF, NRAS).
Surgical goals: oncologic resection with clear margins; en bloc removal of tumor and regional lymphadenectomy; minimum 12 lymph nodes evaluated; margins: colon cancer 5 cm free margin; rectal cancer distal margin typically 2 cm (1 cm may be acceptable in very distal resections with frozen section guidance).
Resection strategies: open vs laparoscopic vs robotic; MIS advantages include less pain, shorter LOS, faster bowel function return; laparoscopy feasible for many colectomies; robotic approaches offer enhanced precision for pelvic dissection.
Right-sided colonic cancers: right hemicolectomy with division of ileocecal pedicle at SMA origin and division of right colic vessels; ileocecal and transverse colon margins; ileotransverse anastomosis (often extracorporeal or intracorporeal depending on approach).
Transverse colon cancers: extended right hemicolectomy with division of middle colic vessels at their origin; ileocolic anastomosis to distal transverse colon.
Splenic flexure cancers: options include extended right colectomy or left colectomy with splenic flexure mobilization; midline or transverse anastomoses; care to preserve marginal vessels to ensure perfusion.
Left-sided cancers: left hemicolectomy with high ligation of the IMA; detach splenic flexure; mobilize to allow anastomosis to proximal rectum; anastomosis typically performed with a circular stapler transanally or hand-sewn depending on situation; MIS approaches favored when appropriate.
Obstructing cancers: symptoms due to obstruction; stenting as a bridge to surgery may allow better staging and enable less-risky resections; proximal obstruction may require right-sided resection; unfit patients may require stoma creation.
Synchronous cancers: may require extended resections or IPAA depending on sites; in rectal cancer with synchronous colon cancer, IPAA may be indicated; IPAA has significant functional implications and requires careful patient selection.
Perioperative considerations: neoadjuvant therapy for rectal cancer; watch-and-wait for complete clinical response in some rectal cancers; pathologic complete response in some patients; TME (total mesorectal excision) is standard for rectal cancer; circumferential margin quality correlates with local recurrence.
Anastomotic concerns: anastomotic leaks; loop ileostomy often used to protect low pelvic anastomosis; stoma reversal may be delayed; intraoperative endoscopic assessment of anastomosis; management of leaks includes peritoneal lavage, drainage, and possible reoperation; in right-sided surgeries, redo anastomosis or terminal ileostomy if patient instability.
Low Anterior Resection Syndrome (LARS): functional outcome after low rectal resections; bowel function changes including frequency, incontinence, urgency; mitigated by J-pouch, coloplasty, side-to-end anastomosis; pelvic floor rehabilitation and dietary adjustments.
Enhanced Recovery After Surgery (ERAS) and Pelvic Floor Disorders
ERPs include perioperative optimization, analgesia, fluid management, early mobility, early oral intake; avoidance of routine drains and NG tubes; MIS favored when feasible; goal-directed fluid therapy reduces time to return of bowel function and LOS.
Pelvic floor disorders and constipation: rectal prolapse (procidentia), rectocele, cul-de-sac hernia (enterocele/sigmoidocele), anismus (pelvic floor dysfunction).
Diagnostics in pelvic floor disorders: anorectal manometry, defecography, endoanal ultrasound, MRI defecography; colonoscopy for CRC exclusion; Sitzmarks test for colonic transit; defecography can reveal rectocele and rectal intussusception.
Treatments: nonoperative management for mild cases; abdominal and transperineal repairs for prolapse; posterior rectopexy (Ripstein), ventral mesh rectopexy, Altemeier procedure (perineal proctosigmoidectomy), Delorme procedure for small prolapse; STARR for intracavitary rectal prolapse; mesh complications include erosion and fistula; perineal approaches in elderly or high-risk patients; in some cases transanal minimally invasive surgery (TAMIS) is used.
Solitary rectal ulcer syndrome (SRUS): chronic benign disorder with single or multiple ulcers, associated with internal rectal prolapse; typical management includes bowel regimen, fiber supplementation, and anti-inflammatory/topical therapies; surgery reserved for refractory cases (local excision, rectal prolapse repair).
Rectocele management: rectovaginal fistula repair if present; transvaginal approaches favored by gynecologists; perineal and abdominal approaches both used depending on patient and surgeon preference; defecatory symptoms treated with bowel regimen and pelvic floor training; defecography to assess rectocele severity.
Obstacles and Special Scenarios
Right-sided diverticulitis: more common in Asia; younger patients; surgical resection with right hemicolectomy considered for recurrent or uncertain diagnosis; immediate resection for complicated cases or suspicion of cancer.
Ischemic colitis: most common GI ischemia; often distal to watershed areas; diagnosis via CT and flexible endoscopy; management ranges from supportive to emergent colectomy in cases of full-thickness ischemia or perforation; intraoperative indocyanine green angiography used to assess perfusion; high mortality in patients requiring colectomy for ischemic colitis; risk factors include advanced age, comorbidities, shock, renal failure, and delayed surgery.
Toxic megacolon: can occur in UC or Crohn’s and other colitides; criteria include multiple systemic signs; urgent surgery in severe cases; Hartmann or resection with diverting stoma; post-Hartmann stump management to avoid pelvic abscess.
Clostridioides difficile infection (CDI): common healthcare-associated diarrhea; risk factors include antibiotics, hospitalization, and immunosuppression; treatment includes vancomycin or fidaxomicin for initial episodes; metronidazole for non-severe cases; fulminant disease requires urgent surgery (colectomy) with supportive care; fecal microbiota transplantation (FMT) for recurrent CDI; bezlotoxumab/actoxumab monoclonal antibodies as adjuncts; infection prevention and testing guidelines.
Surveillance and Follow-Up of CRC and IBD
Postoperative surveillance for CRC: regular CEA monitoring every 6 months for 5 years, then annually; colonoscopy at 1 year post-op, then every 3 years if no adenomas, then yearly if adenomatous polyps; chest/abdomen CT annually; surveillance guidelines from ASCRS.
IBD patients require ongoing endoscopic surveillance for dysplasia/cancer risk, particularly UC with long-standing disease; chromoendoscopy may help identify dysplasia; dysplasia management (endoscopic resection or colectomy) depends on distribution and grade; watchful surveillance is essential especially when maintaining an ileal pouch.
Prophylaxis and immunosuppression: use of NSAIDs and NSAID-related GI risk in at-risk patients with IBD requires careful management; post-surgical infection risk increases with preoperative immunosuppressants; discuss temporary stomas to reduce postoperative complications when disease activity is high.
Practical and Ethical Implications
Patient-centered decision-making for complex colectomies and IPAA: weighing quality of life after extensive resections vs oncologic risk; discussion of stool frequency and continence with IPAA vs IRA or end ileostomy.
For hereditary syndromes, genetic counseling and testing implications; screening initiation ages must balance risk with patient life plans, including reproductive decisions and pregnancy planning.
Watchful waiting vs immediate surgery in certain rectal cancers after neoadjuvant therapy presents ethical considerations regarding risk of recurrence and patient autonomy.
Use of biologic therapies prior to surgery: potential increased infection risk; plan for perioperative management, possible temporary diversion to reduce risk of leaks.
Staging and margin decisions for rectal cancer: the balance between sphincter-sparing procedures and oncologic clearance; patient preferences and pelvic anatomy must be considered.
Key Formulas and Numerical References (LaTeX)
Rectum lengths and margins:
Upper rectum length:
Middle rectum:
Lower rectum:
Distal margin for rectal cancer: ; ultradistal sphincter-sparing may allow margins in select cases with intraoperative frozen section.
Stoma aperture sizing: typically enough to admit two fingers; balance between adequate transit and avoiding hernia.
Diverticular disease tissue planes: Hartmann procedure vs primary anastomosis with diverting ileostomy; stoma decisions based on stability and tissue viability in the pelvis.
Budgets and Recurrence Projections:
Seventh edition: 5-year cancer recurrence curves; lymph node count minimum: at least nodes required for oncologic adequacy; more nodes often retrieved in resections.
Surgical margins and lymph nodes: 5 cm free margin for colon cancer; 2 cm distal margin for rectal cancer; lymphadenectomy aims for at least nodes; adequate margins reduce local recurrence.
Staging: TNM (T, N, M) categories used in AJCC 8th edition; cTNM, pTNM, ypTNM used for therapy planning.
Selected Tables and Classifications (Summary)
Hinchey classification (diverticulitis severity): Grade 0, Ia, Ib, II, III, IV with corresponding pericolic inflammation, abscesses, and peritonitis levels.
Haggitt classification for pedunculated polyps: Level 0 to Level 4 indicating depth of invasion into stalk or submucosa; higher levels carry higher metastatic risk.
Kikuchi classification for sessile polyps with invasion into submucosa: Sm1–Sm3 levels.
Spigelman classification for duodenal polyposis in FAP: stages I–IV based on polyp number, size, histology, and dysplasia.
Amsterdam II criteria and Bethesda criteria for Lynch syndrome testing (box references).
Table 52.3: Pharmacologic therapies for IBD: biologics, antiinflammatory, immunosuppressants, probiotics, antibiotics; administration routes and indications.
Table 52.6: Post-polypectomy surveillance intervals depending on polyp type, size, and pathology.
// End of comprehensive notes for Chapter 52: Colon and Rectum